Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-Analysis
Cytomegalovirus (CMV) is a common infection occurring in patients undergoing solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HSCT). CMV-specific hyperimmunoglobulin (CMVIG) has been used for the past four decades and is typically administered either prophylactically or...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/12/3/361 |
| _version_ | 1827628559197274112 |
|---|---|
| author | Markus J. Barten Fausto Baldanti Alexander Staus Christian M. Hüber Kyriaki Glynou Andreas Zuckermann |
| author_facet | Markus J. Barten Fausto Baldanti Alexander Staus Christian M. Hüber Kyriaki Glynou Andreas Zuckermann |
| author_sort | Markus J. Barten |
| collection | DOAJ |
| description | Cytomegalovirus (CMV) is a common infection occurring in patients undergoing solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HSCT). CMV-specific hyperimmunoglobulin (CMVIG) has been used for the past four decades and is typically administered either prophylactically or pre-emptively. The present meta-analysis evaluated CMV infection rates in SOT patients who received prophylactic CMVIG. PubMed and the Cochrane Library were searched for studies published up to October 2021. The primary endpoint was CMV infection rate. Thirty-two SOT studies were identified (n = 1521 CMVIG-treated and n = 1196 controls). Prophylactic CMVIG treatment was often associated with a lower risk of CMV infection in transplant recipients. The average CMV infection rate was 35.8% (95% confidence interval [CI]: 33.4–38.2%) in patients treated prophylactically with CMVIG and 41.4% (95% CI: 38.6–44.2%) in the control group not receiving CMVIG (p = 0.003). Similar results were observed in analyses limited to publications evaluating currently available CMVIG products (Cytotect CP and Cytogam; p < 0.001). In combination with the established safety profile for CMVIG, these results suggest that prophylactic CMVIG treatment in patients undergoing solid organ transplantation may be beneficial, particularly in those at high risk of CMV infection or disease. |
| first_indexed | 2024-03-09T13:35:11Z |
| format | Article |
| id | doaj.art-936449f71326489f9571aeeabdb39b6d |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-09T13:35:11Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-936449f71326489f9571aeeabdb39b6d2023-11-30T21:13:38ZengMDPI AGLife2075-17292022-03-0112336110.3390/life12030361Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-AnalysisMarkus J. Barten0Fausto Baldanti1Alexander Staus2Christian M. Hüber3Kyriaki Glynou4Andreas Zuckermann5Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, 20246 Hamburg, GermanyDepartment of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, 27100 Pavia, ItalyBiotest AG, 63303 Dreieich, GermanyBiotest AG, 63303 Dreieich, GermanyBiotest AG, 63303 Dreieich, GermanyDivision of Cardiac Surgery, Medical University of Vienna, 1090 Vienna, AustriaCytomegalovirus (CMV) is a common infection occurring in patients undergoing solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HSCT). CMV-specific hyperimmunoglobulin (CMVIG) has been used for the past four decades and is typically administered either prophylactically or pre-emptively. The present meta-analysis evaluated CMV infection rates in SOT patients who received prophylactic CMVIG. PubMed and the Cochrane Library were searched for studies published up to October 2021. The primary endpoint was CMV infection rate. Thirty-two SOT studies were identified (n = 1521 CMVIG-treated and n = 1196 controls). Prophylactic CMVIG treatment was often associated with a lower risk of CMV infection in transplant recipients. The average CMV infection rate was 35.8% (95% confidence interval [CI]: 33.4–38.2%) in patients treated prophylactically with CMVIG and 41.4% (95% CI: 38.6–44.2%) in the control group not receiving CMVIG (p = 0.003). Similar results were observed in analyses limited to publications evaluating currently available CMVIG products (Cytotect CP and Cytogam; p < 0.001). In combination with the established safety profile for CMVIG, these results suggest that prophylactic CMVIG treatment in patients undergoing solid organ transplantation may be beneficial, particularly in those at high risk of CMV infection or disease.https://www.mdpi.com/2075-1729/12/3/361cytomegalovirusCMV infectionhuman CMV hyperimmunoglobulinCMVIGprophylaxistransplantation |
| spellingShingle | Markus J. Barten Fausto Baldanti Alexander Staus Christian M. Hüber Kyriaki Glynou Andreas Zuckermann Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-Analysis Life cytomegalovirus CMV infection human CMV hyperimmunoglobulin CMVIG prophylaxis transplantation |
| title | Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-Analysis |
| title_full | Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-Analysis |
| title_fullStr | Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-Analysis |
| title_short | Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-Analysis |
| title_sort | effectiveness of prophylactic human cytomegalovirus hyperimmunoglobulin in preventing cytomegalovirus infection following transplantation a systematic review and meta analysis |
| topic | cytomegalovirus CMV infection human CMV hyperimmunoglobulin CMVIG prophylaxis transplantation |
| url | https://www.mdpi.com/2075-1729/12/3/361 |
| work_keys_str_mv | AT markusjbarten effectivenessofprophylactichumancytomegalovirushyperimmunoglobulininpreventingcytomegalovirusinfectionfollowingtransplantationasystematicreviewandmetaanalysis AT faustobaldanti effectivenessofprophylactichumancytomegalovirushyperimmunoglobulininpreventingcytomegalovirusinfectionfollowingtransplantationasystematicreviewandmetaanalysis AT alexanderstaus effectivenessofprophylactichumancytomegalovirushyperimmunoglobulininpreventingcytomegalovirusinfectionfollowingtransplantationasystematicreviewandmetaanalysis AT christianmhuber effectivenessofprophylactichumancytomegalovirushyperimmunoglobulininpreventingcytomegalovirusinfectionfollowingtransplantationasystematicreviewandmetaanalysis AT kyriakiglynou effectivenessofprophylactichumancytomegalovirushyperimmunoglobulininpreventingcytomegalovirusinfectionfollowingtransplantationasystematicreviewandmetaanalysis AT andreaszuckermann effectivenessofprophylactichumancytomegalovirushyperimmunoglobulininpreventingcytomegalovirusinfectionfollowingtransplantationasystematicreviewandmetaanalysis |